Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
- Sumitomo Wins Approval for Antibiotic Xenleta in China
November 24, 2023
- Otsuka’s UK Unit Astex to Receive Milestone Payment from AstraZeneca
November 24, 2023
- Lilly Restricts Shipments of Humalog, Lyumjev in Spillover from Novo’s Insulin Curb
November 22, 2023
- Alfresa Boosts Biz Alliance with Major Chinese Wholesaler
November 22, 2023
- BMS Japan Has Busy Years Ahead with String of Launches towards Doubling of Sales
November 22, 2023
- Daiichi Sankyo Wins ADC Patent Row against Seagen, Appeals Unfavorable Ruling in Enhertu Suit
November 21, 2023
- Janssen Files FGFR Inhibitor Erdafitinib for Urothelial Cancer in Japan
November 21, 2023
- Lagevrio Japan’s Top-Seller Drug in July-September, 2 Other COVID Meds Make Top 10: IQVIA
November 20, 2023
- Santen Snags European OK for Glaucoma/Ocular Hypertension Drug
November 20, 2023
- Xtandi Approved in US for Prostate Cancer in Earlier Setting
November 20, 2023
- Janssen Files Bispecific Antibody Amivantamab for NSCLC in Japan
November 20, 2023
- Takeda Files CMV Drug Maribavir in Japan
November 20, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- Astellas to Acquire US Upstart Propella for Prostate Cancer Drug
November 17, 2023
- Japanese Pricing Rules Don’t Fully Capture Value of New Modalities, “No” to CEA Expansion: Janssen Exec
November 17, 2023
- Novo Nordisk Curbs Insulin Shipments Due to Surge in Demand for Diabetes Meds
November 17, 2023
- Astellas, University of Tsukuba Tie Up in Drug Discovery and Startup Incubation
November 17, 2023
- Xocova, Dayvigo Again Winner in Sept Rep Promotion Rankings for GPs, HPs: Intage
November 17, 2023
- AbbVie Japan Files Rinvoq 30 mg Regimen for Age 12-Plus Atopic Dermatitis Patients
November 16, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…